Abstract: | This perspective is a paper discussing drugs dropped from clinical development in the previous years. Specifically, this paper focuses on 16 cardiovascular drugs discontinued in 2010 after reaching Phase I – III clinical trials. Information for this perspective is mainly derived from a search of Pharmaprojects. |